Clinical Trial Details Page
LCCC 1317
- Objective
Genotype-Directed Phase II Study of Higher Dose of Irinotecan in First-Line Metastatic Colorectal Cancer Patients Treated with Folfiri Plus Bevacizumab.
- IRB Protocol Number
- NCT02138617
-
Clinical Trial Categories
- Contact
- Nancy Burns at 919-784-7209
or Nancy.Burns2@unchealth.unc.edu
- How to Participate
View eligibility criteria and additional study information.